(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/172917 A1

(51) International Patent Classification:
A61K 35/17 (2015.01) *A61K 39/00* (2006.01)
A61K 38/20 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2023/063869

(22) International Filing Date:
07 March 2023 (07.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/317,253 07 March 2022 (07.03.2022) US

(71) Applicant: **SANOFI-AVENTIS U.S. LLC** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors; and

(71) Applicants: **BLONDEL, Marielle Chiron** [FR/FR]; c/o SANOFI, Département Brevets, 1 avenue Pierre Brossolette, 91380 Chilly-Mazarin (FR). **DESJONQUERES, Alexandre** [FR/FR]; c/o SANOFI, Département Brevets, 1 avenue Pierre Brossolette, 91380 Chilly-Mazarin (FR). **KLIPPEL, Zandra Karina** [US/FR]; c/o SANOFI, Département Brevets, 1 avenue Pierre Brossolette, 91380 Chilly-Mazarin (FR). **MELONI, Marco** [IT/FR]; c/o SANOFI, Département Brevets, 1 avenue Pierre Brossolette, 91380 Chilly-Mazarin (FR). **VIRONE-ODDOS, Angela** [FR/FR]; c/o SANOFI, Département Brevets, 1 avenue Pierre Brossolette, 91380 Chilly-Mazarin (FR).

(74) Agent: **ONUFRYK, Christina** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2023/172917 A1

(54) Title: USE OF ISATUXIMAB IN COMBINATION WITH OTHER AGENTS FOR THE TREATMENT OF MULTIPLE MYELOMA

(57) Abstract: The present disclosure provides methods for treating multiple myeloma comprising administering an anti-CD38 antibody and an Interleukin-2 analog to an individual in need thereof and optionally administering Natural Killer (NK) cells having expression of CD38 reduced or knocked-out.